サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1739181

変色性白質ジストロフィー治療の世界市場

Metachromatic Leukodystrophy Treatment

出版日
ページ情報
英文 283 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
変色性白質ジストロフィー治療の世界市場
出版日: 2025年05月23日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 283 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

変色性白質ジストロフィー治療の世界市場は2030年までに33億米ドルに到達

2024年に26億米ドルと推定される変色性白質ジストロフィー治療の世界市場は、2024～2030年の分析期間においてCAGR 4.4%で成長し、2030年には33億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるAtidarsagene Autotemcel Drug Typeは、CAGR 5.3%を記録し、分析期間終了時には18億米ドルに達すると予測されます。DUOC-01薬剤タイプセグメントの成長率は、分析期間中CAGR 2.8%と推定されます。

米国市場は6億9,790万米ドルと推定、中国はCAGR 8.2％で成長すると予測

米国の変色性白質ジストロフィー治療市場は、2024年に6億9,790万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに6億9,180万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.7%と3.6%と予測されています。欧州では、ドイツがCAGR 2.6%で成長すると予測されています。

世界の変色性白質ジストロフィー治療市場- 主要動向と促進要因まとめ

なぜメタクロマチック白質ジストロフィーは緊急かつ専門的な治療戦略を必要とするのか？

メタクロマチック白質ジストロフィー（MLD）は、脳や末梢神経系の神経細胞を包む保護鞘であるミエリンの破壊が進行する、まれな遺伝性リソソーム貯蔵障害です。アリルスルファターゼA（ARSA）という酵素の欠損が原因となり、オリゴデンドロサイトやシュワン細胞にとって有毒なスルファチドが蓄積します。この疾患は重篤で、しばしば致死的であり、幼児期後期型、若年型、成人型があり、それぞれ症状の発現や進行速度が異なります。

典型的な症状としては、運動機能の低下、痙縮、認知機能の低下、発作、言語能力や運動能力の低下などがあり、患者は診断から数年以内に完全に依存状態に陥る。長年の間、治療法がなかったため、対症療法が治療の中心でした。しかし、遺伝子治療、酵素補充療法、造血幹細胞移植（HSCT）の画期的な進歩により、現在では治療の可能性が再定義されつつあります。早期診断が効果に不可欠であることから、新生児スクリーニング、早期介入、高精度の遺伝子ターゲティングが市場の中心となってきています。

遺伝子治療と酵素ベースのアプローチは治療パラダイムをどのように変えているのか？

遺伝子治療の登場は、MLD治療に転機をもたらしました。最も注目すべき技術革新は、Orchard Therapeutics社が開発した、MLDに対して初めて承認された生体外遺伝子治療薬であるLibmeldy（atidarsagene autotemcel）です。この治療法では、患者の造血幹細胞を取り出し、レンチウイルスベクターを用いてARSA遺伝子の機能的コピーを挿入し、骨髄切除コンディショニング後に改変細胞を再注入します。この方法は、症状が現れる前の早い時期に行うことで、特に症状が現れる前の患者において、病気の進行を止めたり、遅らせたりすることに大きな可能性を示しています。

酵素補充療法（ERT）と基質減少療法（SRT）も研究されています。遺伝子組換えARSA酵素を静脈内あるいは髄腔内に投与し、血液脳関門を通過して欠損した活性を補充する方法が試験されています。スルファチドの蓄積を減少させる低分子化合物や変異酵素を安定化させるシャペロン療法などの補助的な戦略も、前臨床試験で人気を集めています。この分野は、バイオファーマ企業、希少疾患財団、希少疾病用医薬品の開発や早期承認の道を優先する規制当局の協力によって急速に進展しています。

どのような患者集団、研究機関、地域が治療開発を牽引しているか？

主な患者集団は、MLDの小児型後期および若年型と診断された小児で、発症が早く、減退が早いため、臨床介入において最大のシェアを占めています。これらの患者は通常、家族歴、神経学的評価、または希少疾患サーベイランスプログラムを実施している国における新生児スクリーニングパネルの拡大によって診断されます。成人発症のMLD患者は、より稀で進行が遅いもの、治療方針やバイオマーカー開発の理解を深めるため、自然史研究や登録への参加が増加しています。

欧州は依然としてMLD治療開発の主要地域であり、英国、ドイツ、イタリアが複数の臨床センター、共同研究、規制当局によるパイロット試験を実施しています。北米は臨床研究拠点を急速に拡大しており、NIH、メイヨークリニック、CHOPなどの米国機関が臨床試験や長期転帰データに貢献しています。アジア太平洋は、診断インフラ開発の初期段階にあるが、特に日本、韓国、中国において、希少疾患への資金提供、遺伝子治療のローカライゼーション、新生児ゲノム研究への関心が高まっています。

MLD治療市場の長期的成長の原動力と残された課題とは？

MLD治療市場の成長は、プレシジョン・メディシンのブレークスルー、希少疾病用医薬品の優遇措置、診断に対する意識の高まりによってもたらされます。早期承認制度、小児希少疾病クーポン、希少疾病アドボカシーの高まりにより、高リスク・高コストの治療法にとって有利な政策環境が整いつつあります。出生時に遺伝子スクリーニングを実施する国が増えるにつれ、無症候性MLD症例を特定できるようになり、早期治療介入の対象となる人口が拡大します。

こうした進歩にもかかわらず、課題も残されています。高い治療費、製造の複雑さ、限られた治療センターが世界のアクセスを妨げています。長期的な有効性の確保、安全性監視、および1回限りの遺伝子治療に対する公平な償還の仕組みは喫緊の課題です。さらに、成人や進行期の患者には選択肢が限られており、神経再生戦略や中枢神経系指向性酵素デリバリーの継続的な研究が必要です。

遺伝子治療が成熟し、個別化された介入プロトコールが洗練されるにつれて、MLD治療の状況は大きく変化し、かつては治療不可能で壊滅的な神経変性疾患と考えられていたものに希望を与える態勢が整いつつあります。

セグメント

薬剤タイプ（Atidarsagene Autotemcel薬剤タイプ、DUOC-01薬剤タイプ、OTL-200薬剤タイプ、その他薬剤タイプ）;エンドユーザー（病院エンドユーザー、専門クリニックエンドユーザー、その他エンドユーザー）

調査対象企業の例（注目の43社）

  • Abeona Therapeutics Inc.
  • AGTC（Applied Genetic Technologies）
  • Amicus Therapeutics
  • ArmaGen Inc.
  • Asklepios BioPharmaceutical
  • Avrobio Inc.
  • BioMarin Pharmaceutical Inc.
  • bluebird bio, Inc.
  • BridgeBio Pharma
  • Denali Therapeutics Inc.
  • Freeline Therapeutics
  • Genethon
  • GlaxoSmithKline plc（GSK）
  • Homology Medicines, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Krystal Biotech, Inc.
  • Lysogene
  • Magenta Therapeutics
  • Orchard Therapeutics plc
  • Passage Bio, Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP34072

Global Metachromatic Leukodystrophy Treatment Market to Reach US$3.3 Billion by 2030

The global market for Metachromatic Leukodystrophy Treatment estimated at US$2.6 Billion in the year 2024, is expected to reach US$3.3 Billion by 2030, growing at a CAGR of 4.4% over the analysis period 2024-2030. Atidarsagene Autotemcel Drug Type, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the DUOC-01 Drug Type segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$697.9 Million While China is Forecast to Grow at 8.2% CAGR

The Metachromatic Leukodystrophy Treatment market in the U.S. is estimated at US$697.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$691.8 Million by the year 2030 trailing a CAGR of 8.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Global Metachromatic Leukodystrophy Treatment Market - Key Trends & Drivers Summarized

Why Does Metachromatic Leukodystrophy Demand Urgent and Specialized Therapeutic Strategies?

Metachromatic leukodystrophy (MLD) is a rare, inherited lysosomal storage disorder that results in the progressive destruction of myelin-the protective sheath surrounding nerve cells in the brain and peripheral nervous system. Caused by a deficiency in the enzyme arylsulfatase A (ARSA), MLD leads to the accumulation of sulfatides, which are toxic to oligodendrocytes and Schwann cells. The condition is severe, often fatal, and manifests in late-infantile, juvenile, or adult forms, each with varying symptom onset and progression speed.

Symptoms typically include motor regression, spasticity, cognitive decline, seizures, and loss of speech and mobility, rendering patients completely dependent within a few years of diagnosis. The absence of curative options for many years made symptom management the mainstay of care. However, breakthroughs in gene therapy, enzyme replacement, and hematopoietic stem cell transplantation (HSCT) are now redefining therapeutic potential. With early diagnosis being critical to effectiveness, the market is increasingly centered around newborn screening, early intervention, and high-precision genetic targeting.

How Are Gene Therapies and Enzyme-Based Approaches Changing the Treatment Paradigm?

The emergence of gene therapy has marked a turning point in MLD treatment. The most notable innovation is Libmeldy (atidarsagene autotemcel), the first approved ex vivo gene therapy for MLD, developed by Orchard Therapeutics. This therapy involves extracting the patient's hematopoietic stem cells, inserting a functional copy of the ARSA gene using a lentiviral vector, and re-infusing the modified cells after myeloablative conditioning. Administered early-before symptom onset-this approach has shown significant promise in halting or slowing disease progression, particularly in pre-symptomatic patients.

Enzyme replacement therapy (ERT) and substrate reduction therapy (SRT) are also being investigated. Recombinant ARSA enzymes delivered intravenously or intrathecally are being tested to overcome the blood-brain barrier and replenish deficient activity. Adjunct strategies, such as small molecules to reduce sulfatide accumulation or chaperone therapies to stabilize mutant enzymes, are gaining traction in preclinical studies. The field is rapidly advancing through collaboration between biopharma firms, rare disease foundations, and regulatory agencies prioritizing orphan drug development and accelerated approval pathways.

Which Patient Populations, Research Institutions, and Regions Are Driving Therapeutic Development?

The primary patient population comprises children diagnosed with late-infantile and juvenile forms of MLD-who represent the largest share of clinical interventions due to earlier onset and faster decline. These patients are typically diagnosed through family history, neurological assessments, or expanded newborn screening panels in countries with rare disease surveillance programs. Adult-onset MLD patients, while rarer and slower progressing, are increasingly participating in natural history studies and registries to better understand therapeutic windows and biomarker development.

Europe remains the leading region for MLD therapeutic development, with the U.K., Germany, and Italy hosting several clinical centers, research collaborations, and regulatory pilots. North America is rapidly expanding its clinical research footprint, with U.S. institutions like the NIH, Mayo Clinic, and CHOP contributing to trials and long-term outcome data. Asia-Pacific is in earlier stages of diagnostic infrastructure development but is seeing growing interest in rare disease funding, gene therapy localization, and neonatal genomics initiatives, particularly in Japan, South Korea, and China.

What Is Driving Long-Term Growth in the MLD Treatment Market and What Challenges Remain?

The growth in the MLD treatment market is driven by precision medicine breakthroughs, orphan drug incentives, and increased diagnostic awareness. Accelerated approval mechanisms, pediatric rare disease vouchers, and growing rare disease advocacy are creating a favorable policy environment for high-risk, high-cost therapies. As more countries implement genetic screening at birth, the ability to identify pre-symptomatic MLD cases will expand the eligible population for early therapeutic intervention-particularly for gene therapy candidates with time-sensitive efficacy.

Despite these advances, challenges remain. High therapy costs, manufacturing complexity, and limited treatment centers hinder global access. Ensuring long-term efficacy, safety surveillance, and equitable reimbursement mechanisms for one-time gene therapies are pressing concerns. Additionally, adult and advanced-stage patients have limited options, necessitating continued research into neuroregenerative strategies and CNS-directed enzyme delivery.

As genetic therapies mature and personalized intervention protocols are refined, the MLD treatment landscape is poised for significant transformation-offering hope for what was once considered an untreatable and devastating neurodegenerative disorder.

SCOPE OF STUDY:

The report analyzes the Metachromatic Leukodystrophy Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type, Other Drug Types); End-Use (Hospitals End-Use, Specialty Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • Abeona Therapeutics Inc.
  • AGTC (Applied Genetic Technologies)
  • Amicus Therapeutics
  • ArmaGen Inc.
  • Asklepios BioPharmaceutical
  • Avrobio Inc.
  • BioMarin Pharmaceutical Inc.
  • bluebird bio, Inc.
  • BridgeBio Pharma
  • Denali Therapeutics Inc.
  • Freeline Therapeutics
  • Genethon
  • GlaxoSmithKline plc (GSK)
  • Homology Medicines, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • Krystal Biotech, Inc.
  • Lysogene
  • Magenta Therapeutics
  • Orchard Therapeutics plc
  • Passage Bio, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Metachromatic Leukodystrophy Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Focus on Rare Disease Therapeutics Throws the Spotlight on Metachromatic Leukodystrophy Treatment
    • Advancements in Gene Therapy Platforms Drive Development of Curative MLD Interventions
    • Increased R&D Funding for Lysosomal Storage Disorders Spurs Clinical Pipeline Expansion
    • Global Regulatory Incentives and Orphan Drug Designations Strengthen Market Entry Opportunities
    • Expansion of Newborn Screening Programs Accelerates Early Diagnosis and Timely Treatment
    • Breakthroughs in Hematopoietic Stem Cell Transplantation Propel Treatment Efficacy in Pediatric Patients
    • Use of Viral Vectors and Genome Editing Tools Fuels Innovation in Ex Vivo Gene Therapies
    • Increased Collaboration Between Biopharma and Academia Supports Preclinical Study Advancements
    • Surge in Compassionate Use and Expanded Access Programs Accelerates Early Drug Adoption
    • Growing Demand for Multidisciplinary Care Models Strengthens Holistic Treatment Approaches
    • Government Grants and Rare Disease Policy Reforms Create Favorable Development Ecosystems
    • Improved Genetic Testing Technologies Enhance Patient Identification and Trial Enrollment
    • Emergence of Cell-Based and Regenerative Therapies Expands Therapeutic Modalities
    • Clinical Validation of Novel Delivery Systems for CNS-Targeted Therapies Boosts Market Confidence
    • Rising Advocacy by Rare Disease Foundations Spurs Patient Engagement and Clinical Trial Awareness
    • Growth in Pediatric Neurology Infrastructure Enhances Access to Specialized MLD Treatments
    • Limited Competition and High Unmet Need Strengthen Business Case for Innovative Drug Development
    • Rise in Biologics and Protein Replacement Research Generates Opportunities for Novel Modalities
    • Complex Manufacturing and Cost Challenges Drive Demand for Scalable Production Platforms
    • Long-Term Disease Progression Data From Ongoing Trials Supports Market Entry of Gene-Edited Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Metachromatic Leukodystrophy Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Metachromatic Leukodystrophy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Atidarsagene Autotemcel Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Atidarsagene Autotemcel Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Atidarsagene Autotemcel Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for DUOC-01 Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for DUOC-01 Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for DUOC-01 Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for OTL-200 Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for OTL-200 Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for OTL-200 Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Specialty Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Metachromatic Leukodystrophy Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Metachromatic Leukodystrophy Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Metachromatic Leukodystrophy Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Metachromatic Leukodystrophy Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Metachromatic Leukodystrophy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Metachromatic Leukodystrophy Treatment by Drug Type - Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Metachromatic Leukodystrophy Treatment by Drug Type - Percentage Breakdown of Value Sales for Atidarsagene Autotemcel Drug Type, DUOC-01 Drug Type, OTL-200 Drug Type and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Metachromatic Leukodystrophy Treatment by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Metachromatic Leukodystrophy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION